Glucose-6-phosphate dehydrogenase deficiency screening: Difference between revisions
Farima Kahe (talk | contribs) No edit summary |
No edit summary |
||
(3 intermediate revisions by 2 users not shown) | |||
Line 6: | Line 6: | ||
G6PD defeciency screening in [[neonates]] is done routinly in some regions with high [[incidence]]. | G6PD defeciency screening in [[neonates]] is done routinly in some regions with high [[incidence]]. | ||
==Screening== | |||
*G6PD defeciency screening in neonates is done routinly in some regions with high [[incidence]]. <ref name="pmid19177059">{{cite journal |vauthors=Kaplan M, Hammerman C |title=The need for neonatal glucose-6-phosphate dehydrogenase screening: a global perspective |journal=J Perinatol |volume=29 Suppl 1 |issue= |pages=S46–52 |date=February 2009 |pmid=19177059 |doi=10.1038/jp.2008.216 |url=}}</ref> | *G6PD defeciency screening in neonates is done routinly in some regions with high [[incidence]]. <ref name="pmid19177059">{{cite journal |vauthors=Kaplan M, Hammerman C |title=The need for neonatal glucose-6-phosphate dehydrogenase screening: a global perspective |journal=J Perinatol |volume=29 Suppl 1 |issue= |pages=S46–52 |date=February 2009 |pmid=19177059 |doi=10.1038/jp.2008.216 |url=}}</ref> | ||
*Screening test is quantitative laboratory assay for G6PD enzyme activity. | |||
*Screening is done before giving [[oxidant]] medication to high risk patients. | *Screening is done before giving [[oxidant]] medication to high risk patients. | ||
*There is insufficient evidence to recommend routine screening for G6PD deficiency. | *There is insufficient evidence to recommend routine screening for G6PD deficiency. | ||
==References== | ==References== |
Latest revision as of 18:41, 25 October 2018
Glucose-6-phosphate dehydrogenase deficiency Microchapters |
Differentiating Glucose-6-phosphate dehydrogenase deficiency from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Glucose-6-phosphate dehydrogenase deficiency screening On the Web |
American Roentgen Ray Society Images of Glucose-6-phosphate dehydrogenase deficiency screening |
FDA on Glucose-6-phosphate dehydrogenase deficiency screening |
CDC on Glucose-6-phosphate dehydrogenase deficiency screening |
Glucose-6-phosphate dehydrogenase deficiency screening in the news |
Blogs on Glucose-6-phosphate dehydrogenase deficiency screening |
Directions to Hospitals Treating Glucose-6-phosphate dehydrogenase deficiency |
Risk calculators and risk factors for Glucose-6-phosphate dehydrogenase deficiency screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahda Alihashemi M.D. [2]
Overview
G6PD defeciency screening in neonates is done routinly in some regions with high incidence.
Screening
- G6PD defeciency screening in neonates is done routinly in some regions with high incidence. [1]
- Screening test is quantitative laboratory assay for G6PD enzyme activity.
- Screening is done before giving oxidant medication to high risk patients.
- There is insufficient evidence to recommend routine screening for G6PD deficiency.
References
- ↑ Kaplan M, Hammerman C (February 2009). "The need for neonatal glucose-6-phosphate dehydrogenase screening: a global perspective". J Perinatol. 29 Suppl 1: S46–52. doi:10.1038/jp.2008.216. PMID 19177059.